Masimo (NASDAQ:MASI) Updates Q4 2025 Earnings Guidance

Masimo (NASDAQ:MASI) issued an update on its fourth quarter 2025 earnings guidance on Monday morning. The company provided EPS guidance of 1.540- for the period, compared to the consensus EPS estimate of 1.440. The company issued revenue guidance of $411.0 million-$411.0 million, compared to the consensus revenue estimate of $407.1 million.

Masimo Stock Down 4.8%

Shares of NASDAQ:MASI opened at $132.23 on Tuesday. The company has a quick ratio of 1.92, a current ratio of 2.84 and a debt-to-equity ratio of 0.69. The firm has a market cap of $7.10 billion, a P/E ratio of -12.55, a P/E/G ratio of 1.42 and a beta of 1.26. Masimo has a 12 month low of $125.94 and a 12 month high of $194.88. The company’s 50-day moving average price is $139.81 and its two-hundred day moving average price is $146.82.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Tuesday, November 4th. The medical equipment provider reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.12. Masimo had a negative net margin of 33.20% and a positive return on equity of 33.04%. The firm had revenue of $371.20 million during the quarter, compared to analysts’ expectations of $366.89 million. During the same quarter in the previous year, the company posted $0.86 EPS. Masimo’s revenue was up 8.2% on a year-over-year basis. Masimo has set its FY 2025 guidance at 5.620-5.790 EPS. As a group, research analysts forecast that Masimo will post 4.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have issued reports on MASI. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research note on Monday, December 1st. Bank of America started coverage on Masimo in a report on Monday, November 17th. They set a “neutral” rating and a $162.00 price objective for the company. Zacks Research cut Masimo from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 24th. Wall Street Zen upgraded Masimo from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Finally, BTIG Research upped their price objective on Masimo from $198.00 to $200.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $189.40.

Hedge Funds Weigh In On Masimo

A number of institutional investors have recently modified their holdings of MASI. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Masimo by 0.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,371 shares of the medical equipment provider’s stock worth $1,894,000 after acquiring an additional 66 shares in the last quarter. Orion Porfolio Solutions LLC grew its stake in shares of Masimo by 2.2% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 4,871 shares of the medical equipment provider’s stock worth $819,000 after acquiring an additional 104 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Masimo by 12.3% in the second quarter. Tower Research Capital LLC TRC now owns 1,516 shares of the medical equipment provider’s stock valued at $255,000 after purchasing an additional 166 shares during the last quarter. Thrivent Financial for Lutherans boosted its holdings in Masimo by 1.7% during the second quarter. Thrivent Financial for Lutherans now owns 10,596 shares of the medical equipment provider’s stock worth $1,782,000 after purchasing an additional 177 shares during the last quarter. Finally, Advisory Services Network LLC bought a new stake in Masimo in the 3rd quarter worth about $46,000. 85.96% of the stock is owned by institutional investors and hedge funds.

Masimo Company Profile

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.